PHILADELPHIA, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the company will attend the upcoming 2026 Jefferies Global Healthcare Conference in London on November 18, 2026. If you are interested in a 1x1 meeting with the Century Therapeutics team during the conference, please reach ou
Detailed price information for Century Therapeutics Inc (IPSC-Q) from The Globe and Mail including charting and trades.
Detailed price information for Century Therapeutics Inc (IPSC-Q) from The Globe and Mail including charting and trades.
Century Therapeutics' CNTY-813 aims to deliver insulin-producing islets without chronic systemic immunosuppression. Find out why IPSC stock is a buy.
Detailed price information for Century Therapeutics Inc (IPSC-Q) from The Globe and Mail including charting and trades.
PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced the appointment of Joseph Truitt to its Board of Directors. Truitt currently serves as Chief Executive Officer and a member of the Board of Directors of iECURE, Inc., a clinical-stage biotechnology company advancing
This is the newest page. Registered accounts read further back.